EUCTR2005-003778-13-DE进行中（未招募）不适用
A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Hyperphenylalaninemia Due to Primary BH4 Deficiency
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Individuals eligible to participate in this study include those who meet all of the following criteria:
- •Documented history of blood Phe level > 180 µmol/L on at least one occasion.
- •Established diagnosis of HPA due to primary BH4 deficiency with a documented defect in biopterin metabolism with blood or urine tests.
- •Willing and able to provide written informed consent or, in the case of subjects under the age of 18 years, provide written assent (if required) and written informed onsent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures
- •Negative urine pregnancy test at screening for females, if determined by the PI to be of child-bearing potential
- •Male and female subjects of childbearing potential (if sexually active and non sterile) must be using acceptable birth control measures, as determined by the investigator, and willing to continue to use acceptable birth control measures while participating in the study
- •Willing and able to comply with all study procedures
- •Able to take medication orally
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Individuals not eligible to participate in this study include those who meet any of the following criteria:
- •Perceived to be unreliable or unavailable for study participation or, if under the age of 18 years, have parents or legal guardians who are perceived to be unreliable or
- •unavailable
- •Use of any investigational agent (other than BH4) within 30 days prior to screening,
- •or requirement for any investigational agent or vaccine prior to completion of all
- •scheduled study assessments
- •Positive urine pregnancy test at screening (non-sterile females of child bearing
- •potential only), already known to be pregnant or breastfeeding or planning a
- •pregnancy in self or partner during the study
- •Female subjects of child bearing potential must be using an effective method of birth control, as determined by the PI, and willing to continue to use acceptable birth
- •control measures
- •ALT > 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening
- •Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid–dependent asthma or other condition requiring oral or parenteral corticosteroid administration, insulin-dependent diabetes, or history of organ transplantation)
- •Serious neuropsychiatric illness (e.g., major depression) not currently under medical
- •Requirement for concomitant treatment with any drug known to inhibit folate
- •synthesis (e.g., methotrexate)
- •Clinical diagnosis of PKU due to phenylalanine hydroxylase deficiency
- •Any condition that, in the view of the PI, renders the subject at high risk from
- •treatment compliance and/or completing the study
研究者
相似试验
进行中（未招募）
1 期
The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing TumorsEUCTR2020-001574-29-PLAstraZeneca AB280
进行中（未招募）
1 期
The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing TumorsTreatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001574-29-ITASTRAZENECA AB280
进行中（未招募）
1 期
The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing TumorsTreatment in locally advanced unresectable metastatic patients with HER2 overexpressed (IHC 3+ or IHC 2+) and HER2 low (1+) selected solid tumors not eligible for curative therapy.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001574-29-BEAstraZeneca AB280
进行中（未招募）
1 期
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphomaEUCTR2015-005173-20-ATCelgene International II Sàrl45
进行中（未招募）
1 期
A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphomaPreviously untreated, high-risk diffuse-large B-cell lymphoma (DLBCL)MedDRA version: 20.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005173-20-EECelgene International II Sàrl120